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Abstract
Pregnancy is characterized by a complexity of metabolic processes that may impact fetal
development and ultimately, infant health outcomes. However, our understanding of whole
body maternal and fetal metabolism during this critical life stage remains incomplete. The
objective of this study is to utilize metabolomics to profile longitudinal patterns of fasting
maternal metabolites among a cohort of non-diabetic, healthy pregnant women in order to
advance our understanding of changes in protein and lipid concentrations across gestation,
the biochemical pathways by which they are metabolized and to describe variation in mater-
nal metabolites between ethnic groups. Among 160 pregnant women, amino acids, tricar-
boxylic acid (TCA) cycle intermediates, keto-bodies and non-esterified fatty acids were
detected by liquid chromatography coupled with mass spectrometry, while polar lipids were
detected through flow-injected mass spectrometry. The maternal plasma concentration of
several essential and non-essential amino acids, long-chain polyunsaturated fatty acids,
free carnitine, acetylcarnitine, phosphatidylcholines and sphingomyelins significantly
decreased across pregnancy. Concentrations of several TCA intermediates increase as
pregnancy progresses, as well as the keto-body β-hydroxybutyrate. Ratios of specific acyl-
carnitines used as indicators of metabolic pathways suggest a decreased beta-oxidation
rate and increased carnitine palmitoyltransferase-1 enzyme activity with advancing gesta-
tion. Decreasing amino acid concentrations likely reflects placental uptake and tissue bio-
synthesis. The absence of any increase in plasma non-esterified fatty acids is unexpected
in the catabolic phase of later pregnancy and may reflect enhanced placental fatty acid
uptake and utilization for fetal tissue growth. While it appears that energy production
through the TCA cycle increases as pregnancy progresses, decreasing patterns of free car-
nitine and acetylcarnitine as well as increased carnitine palmitoyltransferase-1 rate and β-
hydroxybutyrate levels suggest a concomitant upregulation of ketogenesis to ensure suffi-
cient energy supply in the fasting state. Several differences in metabolomic profiles
between Hispanic and non-Hispanic women demonstrate phenotypic variations in prenatal
metabolism which should be considered in future studies.
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Introduction
The state of pregnancy is associated with many complex metabolic alterations in order to meet
not only the energetic demands of the developing fetus but also ensure deposition of adequate
energy substrate stores to contribute to neonatal nutritional requirements following birth. Glu-
cose, amino acids (AA) and lipids are all utilized by the fetoplacental unit, and thus maternal
metabolism must adapt, in both the fasting and fed state, to ensure the fetal demands are met
while also ensuring an adequate maternal nutrient supply to cope with the increased physiolog-
ical demands of pregnancy and of labor and lactation. For instance, enhanced ketogenesis dur-
ing fasting serves to meet energy demands while minimizing protein catabolism. Maternal
plasma AA levels are noted to fall during pregnancy [1], related to increased placental uptake,
increased insulin levels, hepatic diversion for gluconeogenesis and uptake by the fetus for use
in protein synthesis and oxidation [2].
To date, our knowledge of alterations in these metabolic processes during pregnancy is gen-
erated from experimental studies in small populations that have relied on specific nutritional
biomarkers to gain an understanding of individual nutrient metabolism [1–5]. Although there
is general consensus that the normal progressive insulin resistance of pregnancy is an underly-
ing driver for many of the observed metabolic adaptations, our understanding remains incom-
plete regarding the specific nutrients, mechanisms and hormonal processes involved.
Metabolomics technology offers enormous potential to increase our knowledge of subtle
changes in maternal metabolism in pregnancy and their relation to maternal nutritional status
and diet in a comprehensive manner. Two recent cross-sectional studies have reported on the
plasma metabolomic profiles of healthy pregnant women [6,7] while a further study examined
urinary metabolomics [8], each using an untargeted analytical approach. While this method
offers potential for a broad range of metabolites to be explored, meaningful interpretation of
the data may be limited by non-specificity for any given metabolite class, and thus it only serves
non-hypothesis driven studies [9]. In contrast, targeted metabolomic techniques facilitate the
profiling of specific metabolites of interest in a given population, to aid in-depth analysis of
metabolic processes in the context of a pre-formed hypothesis. A further limitation of the
recent metabolomic studies in healthy pregnant cohorts was that each employed a cross-sec-
tional design and therefore had different subjects representing each stage of pregnancy. This
precludes reliable assessment of longitudinal changes in metabolism throughout gestation, as
individual genetic or phenotypic characteristics between the subgroups across gestational win-
dows may have influenced metabolite concentrations. For example, significant differences in
metabolomics profiles have been reported between non-pregnant populations from different
geographical locations, which may be attributed to genetic, dietary or gut microbial variations
[10].
Thus, there remains a need to utilize the recent advancements in metabolomics technology
to characterize maternal metabolism across normal, healthy pregnancy while also considering
the influence of inter-individual variations. Increased knowledge in this field would aid our
understanding of the many complex metabolic changes that occur across gestation, paving the
way for future studies to relate such changes and trajectories to various maternal, fetal and
infant factors. The present study aims to fill this gap through the use of targeted metabolomic
technology and a longitudinal design throughout gestation in a relatively large cohort of
healthy, non-diabetic women. The targeted approach facilitates a specific focus on nutritional
metabolites of interest, namely proteins and lipids, as we hypothesize that distinct changes in
concentrations will occur as gestation advances to reflect the shift from the early pregnancy
anabolic phase to later pregnancy fatty acid catabolism. The present analysis also quantifies
intermediary metabolites generated through carbohydrate, protein and fat metabolism in order
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to deepen our understanding of which nutrients serve as important energy substrates across
gestation. Furthermore, the potential influence of maternal ethnicity on metabolomic profiles
was considered in this sample which predominantly consisted of Hispanic and Non-Hispanic
White pregnant women.
Materials and Methods
This was a secondary analysis conducted within a larger longitudinal, prospective cohort study
designed to investigate the interplay between maternal prenatal stress and offspring develop-
ment at the University of California, Irvine (UCI). The parent study enrolled pregnant women
attending antenatal care at clinics affiliated with the UCI Medical Center, in Orange County,
California between 2011 and 2015, and the present analysis included 167 women enrolled
between March 2011 and December 2013. Women were eligible for inclusion if they were>18
yrs age with a singleton, intrauterine pregnancy and non-diabetic. The University of Califor-
nia’s Institutional Review Board approved the protocol and written, informed consent was
obtained from each participant.
All participants were recruited in the first trimester and prospectively followed until the end
of their pregnancy. Women were invited to attend three prenatal visits for the study, once in
each trimester, which occurred at a mean ± standard deviation gestational age of 13.1±1.8
weeks, 20.5±1.4 weeks and 30.5±1.4 weeks, respectively. Race/ethnicity of the participants was
assessed by self-report at the first study sample. The racial-ethnic breakdown of the study sam-
ple is described in Table 1. Each visit occurred in the morning, following an overnight fast, for
blood sample collection. A 10ml EDTA tube was drawn by standard venipuncture technique
by a trained phlebotomist and then centrifuged for 15 min at 1200 g. Separated plasma aliquots
of 0.5ml were transferred to 2ml screw top plastic vials, labeled and stored at -80°C until analy-
sis. The measurement of polar lipids, AA, tricarboxylic acid (TCA) cycle intermediates, keto-
bodies and NEFA using targeted metabolomic profiling techniques is described below.
Table 1. Subject demographics (N = 160).
Mean (SD)
Maternal age (years) 27.6 (5.5)
Pre-pregnancy weight (kg) 69.0 (16.9)
Height (cm) 163.2 (6.8)
Pre-pregnancy BMI (kg/m2) 25.9 (6.1)
N (%)
Race/Ethnicity:
Hispanic White 51 (31.7)
Hispanic Asian 2 (1.2)
Hispanic Other 15 (9.4)
Non-Hispanic White 68 (42.2)
Non-Hispanic Black 4 (2.5)
Non-Hispanic Asian 12 (7.5)
Non-Hispanic Multi-race 7 (4.3)
Primiparous 67 (41.9)
Prenatal multivitamin supplement use at any stage in pregnancy 141 (88.1)
BMI, body mass index; SD, standard deviation
doi:10.1371/journal.pone.0145794.t001
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Amino acids
Aliquots of 10 μL plasma were prepared using derivatization as previously reported [11]. For
internal standardization, a labeled amino acid standards set (set A, Cambridge Isotope Labo-
ratories) was mixed with L-Asparagine (15N2, 98%, Cambridge Isotope Laboratories) and
L-Tryptophan (Indole-D5, 98%, Cambridge Isotope Laboratories) and added to the precipi-
tation reagent. AA butylester were determined by ion-pair liquid chromatography coupled to
mass spectrometry detection (LC-MS/MS). 10 μL of the prepared sample were injected into
the HPLC system (HPLC 1100, Agilent, Waldbronn, Germany) and chromatographic separa-
tion was performed with a XBridge C18 column (Waters GmbH, Eschborn, Germany). MS
detection was performed with an API 2000 triple quadrupole instrument (Sciex, Darmstadt,
Germany) with an APCI source operating in positive ion ionization mode. Data acquisition
on the mass spectrometer was controlled by Analyst 1.6.2 software (AB Sciex, Darmstadt,
Germany). Data handling and quantification were also performed with Analyst 1.6.2 software
(AB Sciex, Darmstadt, Germany). The sums of non-essential and essential AA were com-
puted in addition to the sum of the branched chain AA (BCAA) leucine, isoleucine and
valine.
TCA Intermediates
Metabolites of the TCA cycle and keto-acids were measured by a modified LC-MS/MS method
based on previously published methods [12,13]. In detail, proteins of 20 μL plasma were pre-
cipitated by adding 200 μL acetonitrile with 0.1% formic acid including D3-methylmalonic acid
as internal standard. After centrifugation and cooling (20min at -20°C), 100 μL of the superna-
tant were evaporated to dryness and re-suspended in 50 μL water. Fife μL of the extracted sam-
ples were injected to an Agilent 1200 HPLC and molecular species were separated on a Kinetex
F5 core-shell HPLC column, 150 x 2.1 mm, 2.6 μm particle size (Phenomenex, Aschaffenburg,
Germany). The mobile phase A was water with 1% formic acid and mobile phase B was com-
posed of methanol/ isopropanol (50:50) with 1% formic acid. The gradient elution at a flow
rate of 200 μL/ min was from 1% B to 85% B within 9 minutes and turned back to initial condi-
tions of 1%B within 1 minute. Re-equilibration was held for 5 minutes at 1% B. The triple
quadrupole mass spectrometer (AB Sciex API4000; Applied Biosystems, Darmstadt, Germany)
was operated in negative scheduled multiple reaction monitoring mode using electrospray ioni-
zation (ESI).
Non-esterified fatty acids
Analysis for NEFA was performed as previously reported [14]. Briefly, 20 μl plasma were
mixed with 200 μl isopropanol containing uniformly labelled palmitic acid (U-13C16, 98%,
Euriso-Top). After centrifugation the supernatant was transferred for LC-MS/ MS analysis.
An UPLC diphenyl column (Pursuit UPS Diphenyl, Varian, Darmstadt, Germany) was used
for chromatographic separation with an Agilent 1200 SL series HPLC system (Waldbronn,
Germany). The injection volume was set to 10 μL with an eluent flow rate of 700 mL/min. A
hybrid triple quadrupole mass spectrometer (4000 QTRAP, AB Sciex, Darmstadt, Germany)
operating in negative ESI mode was coupled to the HPLC system for identification of NEFA.
With the analytical method applied, fatty acids (FA) are separated according to chain length
and number of double bonds, but not according to position of double bonds. NEFA are men-
tioned as CX:Y. In this nomenclature, X is the length of the carbon chain, Y is the number of
double bonds. NEFA sub-groups according to level of saturation were created and the constit-
uents summed.
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Polar Lipids
Flow-injection mass spectrometry (FIA-MS/MS) was used to analyze polar lipids. Ten μl
plasma or 10 μl standard solution were diluted with 500 μl methanol, containing internal
standards for different lipid groups and ammonium-acetate. D3-Carnitine C2, D3-Carnitine
C8, D3-Carnitine C16, 13C6-D-Glucose, (all Cambridge Isotope Laboratories), Lyso-PC
(13:0), and PC(14:0/14:0) (both Avanti Polar Lipids) were used as internal standards. After
centrifugation, 200 μL of the centrifuged supernatant was mixed with 700 μl methanol and
then used for FIA-MS/MS analysis. Samples were analyzed with a triple quadrupole mass
spectrometer (QTRAP4000, Sciex, Darmstadt, Germany) with an ESI source, which was used
in both positive and negative mode. The MS was coupled to a LC system (Agilent, Wald-
bronn, Germany). MS/MS analysis was run in Multiple Reaction Monitoring (MRM) mode.
Analyst 1.6.2 software, followed by in-house processing with the statistical program R (R
Project for Statistical Computing, http://www.r-project.org/) was used to post-process the
entire analytical process.
The analysis comprised acylcarnitines (Carn), diacyl-phosphatidylcholines (PCaa), acyl-
alkyl-phosphatidylcholines (plasmalogens, PCae), sphingomyelins (SM), lysophospholipids
(lyso-PL) and sum of hexoses which is further mentioned as glucose presenting more than 80%
of this value. As a point to note, the analytical technique applied here is not capable of deter-
mining the position of the double bonds and the distribution of carbon atoms between fatty
acid side chains. The polar lipids are mentioned as CX:Y. In this nomenclature, X is the length
of the carbon chain, Y is the number of double bonds, “a” indicates that the acyl chain is bound
via an ester bond to the backbone, while “e” means binding by an ether bond.
Carn sub-groups were created and summed according to chain lengths while each of the
remaining polar lipid families were grouped and their total concentrations summed.
The following ratios of metabolites were also computed as indicators of metabolic pathways:
ratio of various acylcarnitines (C14.0, C16.0, C18.0, C18.1, C18.2) to free carnitine as an indica-
tor of carnitine palmitoyltransferase (CPT)-1 rate; ratio of Carn.a.C2 to each of the acylcarni-
tines C14.0, C16.0, C18.0, C18.1, C18.2 as an indicator of β-oxidation rate.
All metabolites are reported in units of μmol/L plasma.
Quality Control
Six aliquots of a plasma quality control (QC) sample were consistently measured between sam-
ples of one batch to ensure correct quantification of the analytes. The QC criterion was defined
as inter- and intra-batch coefficient of variance of 20%.
As the aim of this longitudinal study was to profile metabolomics among 167 uncompli-
cated, healthy pregnant women, all data from 7 subjects that were diagnosed with diabetes dur-
ing their pregnancies (one with type 1, one with type 2 and 5 with gestational diabetes) were
excluded. Among the remaining 160 participants, blood samples were collected and analyzed
from 142 women at trimester 1, 155 at trimester 2 and 155 at trimester 3. Missing cases within
each trimester were due to non-attendance for blood sample collection. Furthermore, data
from 15 samples which were collected from participants who presented in the non-fasting state
were excluded, resulting in final statistical analysis for N = 135 women at trimester 1, N = 153
at trimester 2 and N = 150 at trimester 3. All participants were followed until delivery to ensure
viable pregnancy outcomes. The mean ± standard deviation gestational age at delivery was 39.4
±1.4 weeks, and mean birth weight was 3360±522 g. All children were healthy at the time of
birth.
Initially, individual outlying values for a given metabolite were detected if>3 times the stan-
dard deviation (SD) of the second highest value. Further possible outliers were detected
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through inspection of boxplots for each metabolite at each time point of measurement and
individual outlying values were removed from the dataset as appropriate.
Statistical Analysis
Statistical analyses were performed using IBM SPSS for Windows, version 22. Normality distri-
butions of metabolites were explored through visual inspection of histograms and many were
found to have a non-normal distribution.
Descriptive statistics were used to describe the median and interquartile range (IQR) of
individual metabolites, groups of metabolites and metabolic ratios within each trimester for the
total population and stratified by Hispanic/non-Hispanic ethnicity. To assist analysis of large
volumes of data, the polar lipids lyso-PL, PCaa, PCae and SM were analyzed by sum of their
sub-groups rather than as individual metabolites. The non-parametric MannWhitney U test
was used to compare median values between ethnic groups within trimesters and the Wilcoxon
Rank test was employed to analyze differences in median values for each parameter between
trimesters among the total population and among both ethnic groups. Bonferroni correction
was applied to address the problem of multiple comparisons (97 metabolites x 3 timepoints),
such that a P-value of 0.05 was divided by 291, to set the level of significance at P<0.00017.
Results of total population differences in metabolites and metabolic ratios between trimesters
were visualized using histograms.
Results
Metabolomic analysis quantified the following metabolites: 21 AA which may be classified as
essential (leucine, isoleucine, valine, methionine, phenylalanine, tryptophan and threonine)
and non-essential (alanine, arginine, asparagine, aspartic acid, glutamine, glutamic acid, gly-
cine, citrulline, ornithine, proline, serine, tyrosine, cysteine and taurine); 21 NEFA which
included 7 saturated (C11:0, C12:0, C14:0, C15:0, C16:0, C17:0, C18:0), 5 monounsaturated
(C14:1, C16:1, C17:1, C18:1, C20:1) and 9 polyunsaturated (C18:2, C18:3, C20:2, C20:3, C20:4,
C20:5, C22:4, C22:5, C22:6) NEFA; 164 polar lipids including sum of hexoses, free carnitine
and 15 Carn (3 short-chain (C2-C4), 5 medium-chain (C8-C12) and 7 long-chain (C14-C18)
acylcarnitines), 17 lyso-PL, 39 PCaa, 37 PCae, 54 SM; and 14 metabolites involved in fatty acid
and amino acid oxidation, among them TCA intermediates, keto acids of BCAA degradation
and keto bodies.
Demographics of the study population are presented in Table 1. The mean body mass index
(BMI), based on self-reported pre-pregnancy weight, was 26 Kg/m2. Forty-two per cent of the
population was of Hispanic ethnicity and 42% were primiparous. While 16% reported using
nicotine products pre-conception, only 6% reported their use at any stage during pregnancy.
The majority of women reported taking any type of prenatal multivitamin supplements,
including folic acid, during their pregnancy.
The subsequent sections describe differences in plasma metabolite concentrations and met-
abolic ratios between Hispanic and non-Hispanic women and changes in these variables across
pregnancy among the total population and stratified by ethnic group. For AA, NEFA, meta-
bolic ratios, and TCA intermediates plus keto-acids, differences in median values between tri-
mesters are visually presented in Figs 1, 2, 3 and 4, respectively (data presented in Tables A-D
in S1 File). Data for polar lipids are presented in Table 2.
Amino acids
Various significant changes in median AA levels are observed across pregnancy (Fig 1). The
sum of BCAA significantly decreases as gestation progresses, driven by changes in leucine and
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valine, although the overall decrease is more pronounced among non-Hispanic women
(Table A in S1 File). While the sum of all essential AA does not reveal any significant changes
across trimesters, when the BCAA are excluded from this group, the sum of the remaining
essential AA significantly increases from first to third trimester. Closer inspection of the indi-
vidual non-branched chain essential AA reveals that threonine alone is driving this group
increase, as it steeply rises by 30 μmol/L between the first and third trimester. Meanwhile,
phenylalanine and tryptophan decrease across pregnancy, while no significant change is
observed in methionine levels. Regarding non-essential AA, there is a general trend towards
decreasing levels across trimesters, with the exception of glutamic acid which is significantly
increased in the third trimester compared to both the first and second trimester levels. There
is a trend towards higher levels of some non-essential AA throughout pregnancy (asparagine,
aspartic acid, citrulline, glycine, glutamine) among non-Hispanic compared to Hispanic
women.
While not definitely an amino acid due to the absence of any carboxyl group, concentrations
of the sulphur-containing organic acid taurine are observed to significantly decrease in the
third trimester compared to the first among all subjects.
Fig 1. Barplot comparing plasma amino acid concentrations across trimesters among pregnant women.Median (+ Interquartile range/2) was plotted.
* p-value < 0.00017, p-value was calculated by Mann-Whitney U Test between trimesters.
doi:10.1371/journal.pone.0145794.g001
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Non-esterified fatty acids
For the saturated and monounsaturated NEFA metabolites, no clear changes over time are
observed across pregnancy (Fig 2), and any differences in concentrations between trimesters
are non-significant after correction for multiple testing. Among the polyunsaturated NEFA, it
is noted that the levels of C18:2 and C18:3 do not significantly change between trimesters
among the total population, although they are higher among Hispanic women in early preg-
nancy (Table B in S1 File). Although the metabolomic analysis technique cannot differentiate
the location of double bonds, it can be assumed that these particular NEFA represent the
omega-3 and omega-6 essential fatty acids, α-linolenic acid and linoleic acid, respectively.
Meanwhile, several long-chain polyunsaturated fatty acids (LC-PUFA) are observed to signifi-
cantly decrease from first to second trimester and remain relatively stable between second and
third trimesters. Ethnic-specific differences are observed for the conditionally essential
LC-PUFA docosahexanoic acid (DHA, C22:6n-3) and eicosapentanoic acid (EPA, C20:5n-3),
which are biosynthesized from C18:3n-3, such that Hispanic women have lower concentrations
than non-Hispanic women and the decrease in DHA with advancing gestation among the total
population is predominantly driven by a decrease in the Hispanic group.
Fig 2. Barplot comparing plasma non-esterified fatty acid concentrations across trimesters among pregnant women.Median (+ Interquartile range/
2) was plotted * p-value < 0.00017, p-value was calculated by Mann-Whitney U Test between trimesters.
doi:10.1371/journal.pone.0145794.g002
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Polar lipids
Longitudinal analysis of Carn levels across pregnancy reveals rather specific changes (Table 2).
Both free carnitine and acetylcarnitine (Carn.a.C2.0), demonstrate a significant decrease across
trimesters, with a similar trend observed among both ethnic groups. Levels of the other short-
chain Carn also significantly decrease although the magnitude of their changes is not as steep.
Meanwhile, first trimester levels of a few medium-chain Carn are significantly higher than lev-
els in later pregnancy, while long-chain Carn levels remain almost completely stable through-
out gestation. Among the remaining polar lipids, lyso-PL significantly decreased across
trimesters while the sum of all PCaa, PCae and SM groups each significantly increased in their
plasma concentrations with advancing gestation among all women regardless of ethnicity.
Among the ratios calculated as indicators of metabolic processes (Fig 3 and Table C in S1
File), each of the 5 ratios used as a possible indicator of CPT-1 rate increased significantly
between trimesters, reflecting the decreasing levels of free carnitine which is used as the
denominator for each ratio. Conversely, the 5 ratios used to indicate β-oxidation rate are each
significantly higher in the first trimester compared to levels in trimesters 2 and 3. This reflects
Fig 3. Barplot comparing metabolic ratios as indicators of β-oxidation (right) and carnitine palmitoyl transferase-1 activity (left) across trimesters
among pregnant women.Median (+ Interquartile range/2) was plotted * p-value < 0.00017, p-value was calculated by Mann-Whitney U Test between
trimesters.
doi:10.1371/journal.pone.0145794.g003
Metabolomic Profiling across Healthy Pregnancy
PLOS ONE | DOI:10.1371/journal.pone.0145794 December 30, 2015 9 / 19
the progressive decrease in Carn.a.C2 across pregnancy, which is the numerator for each β-oxi-
dation ratio.
Metabolites involved in amino acids and fatty acid degradation
Several intermediate metabolites of the TCA cycle, namely citric acid, isocitric acid, α-ketoglu-
taric acid, fumaric acid and malic acid, are significantly increased in concentration in later
pregnancy compared to the first trimester (Fig 4). In particular, citric acid, the first product of
acetyl-CoA metabolism, steadily rises across trimesters in the total population and the individ-
ual ethnic groups. However, pyruvic acid, a common substrate for generation of acetyl-CoA
molecules through glucose oxidation does not significantly change in concentration through-
out pregnancy. Meanwhile, the keto-acids produced from the first stage of BCAA oxidation
demonstrate either minimal change (3-methyl-2-oxobutanoic acid and 3-methyl-2-oxovalveric
acid) or a decrease in concentration (4-methyl-2-oxovalveric acid) across gestation. Beta-
hydroxy-butyric acid, a product of ketogenesis, significantly rises across gestation in the total
population, particularly in the third trimester. Interestingly among non-Hispanic subjects, this
keto-body initially decreases from first to second trimester but then recovers in the third tri-
mester to match the elevated levels of the Hispanic women (Table D in S1 File).
Fig 4. Barplot comparing plasma concentrations of tricarboxylic acid cycle intermediates and keto acids across trimesters among pregnant
women.Median (+ Interquartile range/2) was plotted * p-value < 0.00017, p-value was calculated by Mann-Whitney U Test between trimesters.
doi:10.1371/journal.pone.0145794.g004
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Table 2. Total population and ethnic-specific plasma Carn, Lyso-PL, PC.aa, PC.ae and SM concentrations in μmol/L within each trimester and























Hexosen T1 5538.67 1528.65 5715.43 1420.53 5294.02 1623.63 0.066 T2-T1 0.005 0.068 0.043
T2 5303.97 1775.26 5560.85 1569.46 5193.43 1865.10 0.066 T3-T2 0.018 0.059 0.103
T3 5612.92 1791.11 5896.33 1377.64 5408.94 1436.47 0.013 T3-T1 0.646 0.901 0.701
Free Carnitine T1 26.55 9.89 26.55 9.55 27.09 11.65 0.817 T2-T1 7.080E-20 2.200E-09 7.830E-12
T2 21.24 7.82 21.41 7.40 21.24 8.05 0.975 T3-T2 4.122E-15 1.000E-06 9.730E-10
T3 18.19 6.32 18.63 6.54 18.07 5.95 0.687 T3-T1 2.513E-22 2.280E-10 2.230E-13
Carn.a.C10.1 T1 0.42 0.23 0.41 0.21 0.43 0.29 0.734 T2-T1 1.444E-07 8.500E-05 3.200E-04
T2 0.34 0.22 0.34 0.17 0.35 0.24 0.722 T3-T2 0.008 0.070 0.072
T3 0.30 0.17 0.27 0.16 0.34 0.18 0.073 T3-T1 2.688E-11 3.000E-06 3.000E-06
Carn.a.C12.0 T1 0.11 0.10 0.10 0.09 0.12 0.12 0.438 T2-T1 1.100E-05 0.002 0.001
T2 0.09 0.07 0.10 0.07 0.09 0.07 0.548 T3-T2 0.285 0.165 0.823
T3 0.09 0.07 0.08 0.05 0.10 0.06 0.058 T3-T1 6.090E-08 1.900E-05 7.800E-05
Carn.a.C12.1 T1 0.34 0.22 0.34 0.17 0.37 0.29 0.751 T2-T1 3.444E-07 2.400E-05 0.002
T2 0.27 0.19 0.26 0.15 0.29 0.24 0.230 T3-T2 0.270 0.659 0.306
T3 0.26 0.18 0.23 0.16 0.28 0.23 0.047 T3-T1 6.003E-08 2.600E-05 0.001
Carn.a.C14.0 T1 0.04 0.02 0.03 0.02 0.04 0.02 0.943 T2-T1 6.000E-06 1.33E-04 0.005
T2 0.03 0.02 0.03 0.02 0.03 0.02 0.741 T3-T2 0.026 0.168 0.092
T3 0.04 0.02 0.04 0.02 0.04 0.02 0.401 T3-T1 0.111 0.151 0.392
Carn.a.C14.1 T1 0.11 0.05 0.10 0.06 0.11 0.04 0.548 T2-T1 0.051 0.036 0.363
T2 0.10 0.04 0.10 0.03 0.10 0.05 0.387 T3-T2 0.647 0.193 0.884
T3 0.11 0.04 0.10 0.04 0.11 0.04 0.803 T3-T1 0.065 0.131 0.276
Carn.a.C14.2 T1 0.03 0.02 0.03 0.02 0.03 0.02 0.978 T2-T1 0.003 0.029 0.037
T2 0.03 0.02 0.03 0.01 0.03 0.02 0.656 T3-T2 0.492 0.959 0.384
T3 0.03 0.01 0.03 0.01 0.03 0.01 0.917 T3-T1 0.005 0.018 0.081
Carn.a.C16.0 T1 0.07 0.04 0.07 0.03 0.07 0.04 0.916 T2-T1 0.003 0.299 0.003
T2 0.07 0.03 0.07 0.03 0.07 0.03 0.316 T3-T2 0.529 0.038 0.487
T3 0.07 0.03 0.07 0.03 0.07 0.03 0.298 T3-T1 4.310E-04 0.002 0.055
Carn.a.C18.0 T1 0.03 0.02 0.03 0.02 0.03 0.02 0.541 T2-T1 0.780 0.364 0.267
T2 0.03 0.02 0.03 0.02 0.03 0.02 0.896 T3-T2 0.056 0.168 0.153
T3 0.03 0.02 0.03 0.02 0.03 0.02 0.605 T3-T1 0.078 0.420 0.098
Carn.a.C18.1 T1 0.11 0.06 0.12 0.07 0.11 0.05 0.754 T2-T1 0.036 0.043 0.228
T2 0.11 0.05 0.10 0.05 0.11 0.05 0.444 T3-T2 0.634 0.216 0.755
T3 0.11 0.05 0.10 0.05 0.11 0.04 0.011 T3-T1 0.065 0.006 0.911
Carn.a.C18.2 T1 0.09 0.06 0.08 0.05 0.09 0.05 0.462 T2-T1 0.012 0.397 0.08
T2 0.08 0.04 0.09 0.04 0.08 0.04 0.224 T3-T2 0.281 0.066 0.888
T3 0.08 0.04 0.07 0.04 0.08 0.04 0.222 T3-T1 0.005 0.014 0.096
Carn.a.C2.0 T1 5.30 2.91 5.52 2.73 5.25 3.19 0.894 T2-T1 9.992E-14 1.000E-06 3.452E-08
T2 4.33 2.32 4.55 2.26 4.28 2.39 0.243 T3-T2 9.000E-05 0.002 0.011
T3 3.93 1.79 3.68 2.11 4.01 1.67 0.689 T3-T1 7.664E-18 1.004E-08 1.770E-10
Carn.a.C3.0 T1 0.29 0.13 0.29 0.12 0.29 0.15 0.962 T2-T1 2.450E-09 0.001 1.000E-06
T2 0.25 0.11 0.26 0.10 0.24 0.12 0.192 T3-T2 0.001 0.019 0.018
(Continued)
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T3 0.23 0.11 0.24 0.12 0.21 0.10 0.158 T3-T1 1.924E-16 5.675E-08 8.290E-10
Carn.a.C4.0 T1 0.19 0.10 0.18 0.09 0.20 0.11 0.139 T2-T1 2.440E-04 0.085 0.001
T2 0.18 0.10 0.17 0.09 0.19 0.11 0.436 T3-T2 0.136 0.402 0.240
T3 0.16 0.10 0.16 0.08 0.16 0.08 0.226 T3-T1 2.320E-04 0.012 0.008
Carn.a.C8.1 T1 0.11 0.07 0.11 0.06 0.11 0.08 0.906 T2-T1 0.001 0.008 0.047
T2 0.09 0.06 0.09 0.06 0.09 0.07 0.573 T3-T2 0.477 0.768 0.291
T3 0.09 0.05 0.09 0.05 0.09 0.06 0.759 T3-T1 0.001 0.014 0.028
Carn.a.C9.0 T1 0.02 0.01 0.02 0.01 0.02 0.01 0.003 T2-T1 0.782 0.808 0.732
T2 0.02 0.01 0.01 0.01 0.02 0.02 0.023 T3-T2 0.330 0.815 0.154




T1 5.68 2.65 5.72 2.81 5.69 2.69 0.546 T2-T1 8.456E-10 9.500E-05 3.000E-06
T2 4.25 1.86 4.50 2.16 4.04 1.69 0.098 T3-T2 0.016 0.029 0.244
T3 4.14 1.65 4.14 2.01 4.23 1.55 0.776 T3-T1 1.948E-11 1.900E-05 3.476E-07
Sum of
medium-chain
Carn (N = 5)
T1 1.03 0.06 1.00 0.51 1.05 0.64 0.585 T2-T1 6.171E-08 3.800E-05 2.460E-04
T2 0.84 0.52 0.84 0.45 0.85 0.60 0.319 T3-T2 0.057 0.359 0.108




T1 0.45 0.22 0.48 0.22 0.44 0.19 0.581 T2-T1 0.025 0.051 0.176
T2 0.45 0.20 0.47 0.19 0.43 0.18 0.406 T3-T2 0.749 0.722 0.424




T1 115.82 45.61 114.64 36.38 122.33 55.18 0.188 T2-T1 1.66E-09 1.657E-09 1.657E-09
T2 104.00 37.02 103.23 38.64 104.87 36.47 0.910 T3-T2 2.41E-04 2.410E-04 2.410E-04
T3 97.70 36.47 93.35 34.81 99.87 36.39 0.213 T3-T1 3.21E-12 3.208E-12 3.208E-12
Sum of all
PCaa (N = 39)
T1 2139.44 708.73 2228.00 701.31 2066.33 685.23 0.099 T2-T1 1.68E-11 1.684E-11 1.684E-11
T2 2368.87 801.65 2467.51 896.88 2333.21 721.34 0.142 T3-T2 4.06E-11 4.063E-11 4.063E-11
T3 2657.32 805.97 2668.68 839.64 2624.26 714.32 0.442 T3-T1 2.15E-18 2.155E-18 2.155E-08
Sum of all
PCae (N = 37)
T1 232.84 74.88 232.84 76.93 232.00 70.53 0.748 T2-T1 3.00E-06 3.000E-06 3.000E-06
T2 256.96 83.06 256.84 101.71 259.78 77.20 0.966 T3-T2 0.174 0.174 0.174
T3 262.24 82.07 259.54 84.91 262.46 80.40 0.930 T3-T1 1.87E-08 1.874E-08 1.874E-04
Sum of all SM
(N = 54)
T1 528.91 105.31 554.11 108.36 499.10 142.01 0.043 T2-T1 5.97E-12 6.000E-12 5.965E-12
T2 596.28 137.36 612.32 180.53 571.19 166.82 0.052 T3-T2 2.50E-12 3.000E-12 2.504E-12
(Continued)
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Discussion
To our knowledge, this is the first study to comprehensively describe the longitudinal changes
in maternal metabolites among healthy pregnant women using targeted metabolomic profiling.
To date, the nutritional application of metabolomics in pregnancy has largely focused on those
with glucose intolerance in comparison to women with normal glucose tolerance [15–17] or
the correlation of protein metabolites with fetal growth and intra-uterine growth retardation
[18–19]. While recent cross-sectional studies have provided initial insight to metabolomic pro-
files in healthy pregnancy [7–9], the longitudinal design, broad range of targeted metabolic
products and intermediates analyzed, and consideration of ethnic influences in the present
study provide critical advancement to the characterization of metabolism in pregnancy
through a deeper understanding of changes in the maternal metabolome with advancing gesta-
tion and inter-individual differences by ethnicity.
Amino acids and protein metabolism
The decrease in several maternal plasma AA levels across trimesters is consistent with the con-
cept of placental AA uptake and fetal transfer for protein synthesis [18]. Fetal plasma AA con-
centrations have been reported to be significantly higher than maternal levels [15,20].
Although, we do not have non-pregnant AA levels as a comparison, maternal hypoaminoaci-
daemia in pregnancy is known to occur in the fasted state from as early as the first trimester
and to persist throughout pregnancy [1]. Several AAs are also potential substrates for gluco-
neogenesis in the fasted state, although it is generally accepted that their use in these processes
is diminished during gestation as protein anabolism rather than catabolism is favored [21].
Reduced plasma concentrations of gluconeogenic AAs during pregnancy is thought to contrib-
ute to the accelerated occurrence of fasting hypoglycaemia compared to non-pregnant women
[22,23].
The variations in the changing patterns across trimesters of individual AAs from our data
highlight the unique nature of each AA in pregnancy and metabolism. While the sum of non-
essential AAs does not differ significantly between trimesters, a significant decreasing pattern
in concentrations of arginine, glycine, serine, tyrosine and cysteine is observed. Reduced con-
























T3 664.80 150.15 695.88 226.64 632.79 166.02 0.058 T3-T1 5.89E-18 6.000E-18 5.893E-18
Carn, acylcarnitines; IQR, interquartile range; Lyso-PL, lysophospholipid; PCaa, diacyl-phosphotidylcholine; PCae, acyl-alkyl-phosphotidylcholine; SM,
sphingomyelin.
†P-values represent difference in median metabolite values within a given trimester between ethnic groups, calculated by Mann-Whitney U test.
‡P-values represent difference in median metabolite values between paired trimesters, calculated by Wilcoxon Rank test separately for total population,
Hispanic subjects and non-Hispanic subjects. Signiﬁcance set at p<0.05. Bonferroni correction for multiple comparisons (N = 97*3 timepoints = 291)
implies values are statistically signiﬁcant where p <0.00017 (1.7E-4).
doi:10.1371/journal.pone.0145794.t002
Metabolomic Profiling across Healthy Pregnancy
PLOS ONE | DOI:10.1371/journal.pone.0145794 December 30, 2015 13 / 19
plasma concentration of the essential AA phenylalanine decreases from the first trimester,
probably due to its conservation for nitrogen accretion and tissue synthesis [24] thereby reduc-
ing its availability for its alternative role in tyrosine biosynthesis [25]. In contrast, glutamic acid
significantly increases in the third trimester which is similar to data reported by Di Giulio et al
[19]. We hypothesize that this increase may be related to its reduced conversion to glutamine
secondary to a reduced α-amino nitrogen pool [21], which is reflected in the stable glutamine
levels throughout gestation in our data. The significant increase in the essential AA threonine
with advancing gestation was previously reported [19]. Rees et al [26] studied threonine metab-
olism in the pregnant rat and concluded that dietary protein induced increases in serine-threo-
nine dehydratase activity favored conservation of this AA rather than its oxidation.
Although we report an overall decrease in the sum of BCAA across pregnancy trimesters, it
is specifically leucine and valine which significantly decrease, while plasma isoleucine concen-
trations remain more stable. BCAA are a sub-group of essential AA which may undergo trans-
amination to generate nitrogen for synthesis of non-essential AA such as glutamine and
alanine [27]. Maternal transamination and urea synthesis during pregnancy has been shown to
decrease [21], however, which is supported by the decreased or unchanged concentrations of
α-keto-acids in the current data as these are the initial products of BCAA metabolism. On the
other hand, high activity of the transamination enzymes, branched-chain aminotransferases,
have been found in human placental tissue [28], providing evidence for placental BCAA uptake
where they are transaminated in order to sustain the high placental nitrogen demand that is
used for several metabolic functions including glutamate synthesis [28]. This may also account
for the decreasing pattern of BCAA despite the normal, progressive insulin resistance that
occurs during pregnancy [3], which would conflict with evidence from non-pregnant human
studies reporting higher concentrations of BCAA associated with insulin resistance [29–31].
An alternative potential fate for the AA is their use as substrates for ketogenesis in order to
generate ketone bodies as a source of fuel while maternal glucose supply is low. Plasma samples
for the present study were all collected from women following an overnight fast and as previ-
ously alluded to, a more rapid progression towards hypoglycaemia occurs in pregnant women
in the fasting state, a concept referred to as ‘accelerated starvation’ [23]. In response to this, ini-
tiation of ketogenesis to subsidize maternal energy demands has been reported to occur more
rapidly in pregnancy compared to non-pregnant women [3] and indeed, the increased concen-
tration of β-hydroxybutyrate with advancing gestation in this cohort suggests that ketogenesis
is occurring in the fasted state. However, NEFA also serve as efficient ketogenic substrates and
following the concept of protein accretion in pregnancy, it would be in agreement with existing
evidence surrounding maternal metabolism that NEFA would be the ketogenic substrates of
preference in these fasted subjects.
The decrease in plasma taurine concentrations is likely attributed to uptake by placental and
maternal tissues [32] as adequate reserves of this non-protein AA are critical for fetal growth
and neurodevelopment in the newborn, and reduced urinary excretion during pregnancy has
been previously demonstrated [33].
Non-esterified fatty acids and lipid metabolism
The normal fat deposition in maternal adipose stores associated with early pregnancy is fol-
lowed by lipolysis in late gestation as insulin resistance increases, with lipolytic activity being
further enhanced under fasting conditions [34]. Lipolysis of triacylglycerol in adipose tissue
releases glycerol and NEFA into the maternal circulation where they are transported to periph-
eral tissue and used for energy provision by beta-oxidation and ketogenesis in the fasted state
[4]. Furthermore, NEFA are taken up by the liver for re-synthesis of triacylglycerols. Our data
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does not indicate any increase in plasma NEFA concentrations, however, and where significant
differences in levels do occur between trimesters for LC-PUFA, they relate to reduced concen-
trations in later pregnancy compared to the first trimester.
A fetal supply of LC-PUFA is essential for fetal nervous system development [35]. While
placental uptake of NEFA is possible, evidence suggests that LC-PUFA are preferentially taken
up from the maternal circulation in the form of triacylglycerols present in lipoproteins [36,37].
In addition, FA may be delivered by phospholipids to the placenta, as evidenced by the high
placental phospholipase activity [35]. Thus, the observed reduction in maternal plasma
LC-PUFA in later pregnancy in our data may reflect their conversion to triacylglycerols and/or
phospholipids and subsequent placental uptake. Although we do not have available data on
maternal triacylglycerol concentrations to support this hypothesis, the increasing maternal
plasma concentrations of phosphatidylcholines and sphingomyleins in our data likely indicate
the enhanced role of phospholipids in NEFA transport to the fetus as pregnancy progresses.
Interestingly, the lower baseline levels of DHA and EPA among Hispanic women compared to
non-Hispanic women, despite having higher levels of their precursor α-linolenic acid, would
suggest that non-Hispanic women have a higher dietary intake of these conditionally essential
LC-PUFA which are predominantly sourced from oily fish or nutritional supplements. Indeed,
suboptimal dietary intake of EPA and DHA has been reported among pregnant women of His-
panic ethnicity living in the US [38], and the plasma levels in our data confirm that this is a
nutritional concern which may affect fetal neurological and retinal development [39].
A further explanation for the absence of any increase in plasma NEFA levels in our data
could be enhanced delivery of NEFA to the maternal liver for β-oxidation to acetyl-CoA and
ketone body synthesis. While the concentrations of several TCA cycle intermediates are seen to
increase, pyruvic acid levels remain stable, thus supporting the concept that fatty acids rather
that carbohydrate are being oxidized to generate acetyl-CoA as pregnancy progresses, at least in
the fasted state in this cohort. The concomitant rise in β-hydroxybutyrate also suggests that
NEFA are undergoing ketogenesis as an alternative method of energy production. Fasting
increases adipose tissue lipolysis in late gestation in order to generate a maternal energy supply
when glucose availability is low [4] and the ‘accelerated starvation’ phenomenon of pregnancy
induces ketogenesis after only slightly prolonged periods of fasting [2,37]. In addition to serving
as a maternal energy source, ketone bodies, such as β-hydroxybutyrate, are efficiently transferred
across the placenta to the fetus to serve as fuel and substrates for brain lipid synthesis [37]. The
ethnic-specific analysis of our data suggests that this process takes significant effect only in the
third trimester among non-Hispanic women. Meanwhile, the steady rise in β-hydroxybutyrate
throughout pregnancy among Hispanic women could suggest more efficient metabolic adapta-
tion to fasting earlier in pregnancy, or could be an indicator of alternative dietary patterns in the
second trimester, e.g. not consuming food late in the evening and subsequently undergoing a
longer period of fasting. Furthermore, longitudinal changes in free carnitine and acylcarnitines
provide further insight to the metabolic pathways being utilized throughout gestation.
Free carnitine, acylcarnitines and metabolic ratios
The significant decline in free carnitine and short-chain acylcarnitines across trimesters in our
subjects is in agreement with recent non-targeted metabolomic data from the study by Luan
et al. [7], which also measured these metabolites among different samples of pregnant women
at various stages in gestation. Earlier studies have also reported a decline in plasma free carni-
tine and increased renal excretion of acylcarnitines during pregnancy [40,41]. Carnitine is pri-
marily sourced from dietary intakes of animal protein foods (meat, fish and dairy), but
biosynthesis contributes approximately 25% to circulating carnitine levels [42].
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Carnitine is an essential compound required for fatty acid metabolism, which occurs in the
mitochondria of cells. As NEFA are transported across cell membranes, they are rapidly con-
verted to acyl-Coenzyme A compounds (acyl-CoAs) by fatty acid transport proteins [43]. As
the longer chain acyl-CoAs are impermeable to the inner mitochondrial membrane they must
be converted to long-chain acylcarnitines by CPT1, and are re-converted back to acyl-CoA by
CPT2 once inside the mitochondria [44]. Acyl-CoAs then undergo the β-oxidation cycle which
generates acetyl-CoA molecules. In the fed state, fatty acid oxidation is completed through
transfer of acetyl-CoA to the TCA cycle to generate substrates for the ATP-providing electron
transport chain [43]. Under prolonged fasting conditions, however, the TCA cycle is inhibited
and acetyl-CoA is used to produce ketone bodies as an alternative fuel source through the pro-
cess of ketogenesis [45]. Utilization of acetyl-CoA in ketogenesis decreases the concentrations
of malonyl-CoA, a potent inhibitor of the CPT1 enzyme [42]. This facilitates enhanced fatty
acid metabolism by increasing the rate of acyl-CoA transfer into mitochondria.
This process of fatty acid metabolism also applies to healthy human pregnancy, particularly
in the third trimester when maternal NEFA supply is enhanced with increased lipolytic activity.
The main difference in pregnancy is that the switch from fatty acid oxidation to ketogenesis
appears to occur more rapidly under fasting conditions than in the non-pregnant state, proba-
bly due to increased fetal demands [2]. As previously mentioned, the increased concentrations
of both TCA cycle intermediates and ketone bodies detected in this study suggests enhanced
oxidative and non-oxidative metabolic activity with advancing gestation. Regardless of the
final metabolic fate however, it seems plausible that the reduced free carnitine concentrations
reported in our data among pregnant women following an overnight fast reflect the increased
use of this compound for acyl-CoA transport into mitochondria to provide the necessary sub-
strates for energy production. This is also reflected in the increased ratios for estimating CPT1
activity with advancing gestation, and may be associated with the decreased concentrations of
long-chain NEFA in the second and third trimesters as these are converted to long-chain acyl-
CoAs following transport into cells, the primary substrates for CPT1 activity [43].
However, carnitine is also required by the developing fetus for both fetal maturation and
fatty acid oxidation in the placental-fetal unit [46]. This supply is thought to be primarily met
through placental carnitine uptake from the maternal circulation [47], which therefore may
also contribute to the reduction in maternal plasma carnitine levels throughout pregnancy.
Alternatively, there is evidence that the human placenta and fetus are capable of complete car-
nitine biosynthesis [48]. This mechanism of carnitine production is thought to be particularly
important under conditions of poor maternal carnitine supply, such as in the case of a poor
vegan diet [49]. However, the impact of the maternal fasting state in pregnancy on carnitine
supply to the fetus has not been investigated to our knowledge.
Although we do not have measures of urinary acylcarnitine concentrations, previous reports
of increased urinary excretion of acylcarnitines across pregnancy [40,41,50] may explain the
reduced plasma concentrations of certain carnitine esters among our subjects. The most pro-
nounced decrease in plasma acylcarnitine concentrations was observed for acety-L-carnitine,
which is also a precursor for acetyl-CoA. The metabolomic evidence presented for increasing
rates of TCA cycle activity and fasting-induced ketogenesis with advancing gestation among
this population would increase the demand for acetyl-CoA supply, thus potentially contribut-
ing to the reduced circulating acetyl-L-carnitine levels.
Strengths, Limitations and Future Directions
Our study is strengthened by a relatively large sample size and use of a targeted metobolomic
technique to longitudinally analyze a broad range of distinct nutrient metabolites of interest
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across gestation. The inclusion of intermediates of metabolic processes also facilitated an in-
depth interpretation of the metabolic fate of various nutrients at different stages of gestation,
while stratification of analyses by the dominant ethnic groups offers insight to the potential for
inter-individual variation in prenatal metabolism and/or dietary habits that influence the meta-
bolome and could be addressed through public health measures. The absence of other parame-
ters, such as plasma triglycerides, urinary carnitine esters or tissue protein and lipid
concentrations, however, limits our complete interpretation of metabolomic profiles in these
pregnant subjects. Also, as blood samples were collected from subjects in the fasted state, these
results do not reflect potential changes in the maternal metabolome across gestation that may
occur post-prandial.
This data demonstrates the value of metabolomic research in evaluating whole body metab-
olism, particularly in pregnancy which represents a complexity of metabolic alterations from
the non-pregnant state and with advancing gestation. We provide a foundation for further
metabolomic profiling studies in pregnancy to advance our understanding of maternal and
fetal metabolism during this critical life-stage and highlight the importance of considering eth-
nic or other phenotypic diversity which may impact on the maternal metabolome. Indeed, sub-
tle differences were observed for several metabolites between Hispanic and non-Hispanic
women in this study including some non-essential AA, essential long-chain NEFA and ketone
bodies, all of which may have implications for maternal nutritional status and fetal metabolism.
Knowledge of the flux of nutrients and other metabolites between the maternal and placental-
fetal unit is in its infancy and further metabolomic research in this field may advance our
understanding of the effects of maternal biochemistry, physiology and lifestyle behaviors on
fetal programming and infant outcomes. Thus, there is enormous scope for future studies to
utilize metabolomic techniques to understand alterations in maternal metabolism in response
to different maternal characteristics, dietary intakes, body compositions and hormonal alter-
ations across pregnancy, as well as metabolomic associations with fetal and neonatal outcomes.
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